Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 2

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:

• Rechallenging patients with venetoclax and BTK inhibitors 
• Mechanism by which BTK inhibitors may reduce infusion reactions
• Risk of secondary malignancies with BTK inhibition
• Different cytogenetic findings and adverse event risk

Presenters:

Jeff P. Sharman, MD, Program Director
Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies 
& Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Nicole Lamanna, MD
Associate Attending
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center 
New York, New York

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program, including associated downloadable slidesets:
https://bit.ly/3hATX0L

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.